Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344733 | 1.00 | CRBN (0.46) | CRBNALDH1A1SMN1; SMN2KCNA5BRD4 | |
| SCHEMBL344734 | 1.00 | CRBN (0.46) | CRBNALDH1A1SMN1; SMN2KCNA5BRD4 | |
| SCHEMBL4781825 | 0.92 | CRBN (0.41) | CRBNALDH1A1SMN1; SMN2KCNA5MAPT | |
| SCHEMBL20306102 | 0.86 | CRBN (0.44) | CRBNALDH1A1SMN1; SMN2KCNA5MAPT | |
| SCHEMBL2041963 | 0.85 | KCNA5 (0.48) | CRBNALDH1A1KCNA5MAPT | |
| SCHEMBL1776287 | 0.84 | CRBN (0.40) | CRBNALDH1A1SMN1; SMN2BRD4MAPT | |
| SCHEMBL17832663 | 0.80 | ALDH1A1 (0.37) | CRBNALDH1A1SMN1; SMN2MAPTRECQL | |
| SCHEMBL3632337 | 0.80 | ALDH1A1 (0.37) | CRBNALDH1A1SMN1; SMN2MAPTRECQL | |
| SCHEMBL17823577 | 0.80 | ALDH1A1 (0.37) | CRBNALDH1A1SMN1; SMN2MAPTRECQL | |
| SCHEMBL4379504 | 0.79 | CRBN (0.62) | CRBNALDH1A1SMN1; SMN2KCNA5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398526-A1 | NITROGEN HETEROCYCLIC CARBENE CATALYST AND PREPARATION METHOD THEREFOR | PINGSHAN TRANSLATIONAL MEDICINE CENTER, SHENZHEN BAY LABORATOR (CN) | 2023-12-14 | — | — | US | claimed |
| WO-2022104599-A1 | N-HETEROCYCLIC CARBENE CATALYST AND PREPARATION METHOD THEREFOR | 深圳湾实验室坪山生物医药研发转化中心 | 2022-05-27 | — | — | WO | claimed |
| CN-112625200-A | Covalent organic framework material and preparation method thereof | 中山职业技术学院 | 2021-04-09 | — | — | CN | claimed |
| EP-4413985-B1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-05-06 | — | — | EP | disclosed |
| US-20260092064-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | OPPILAN PHARMA LTD. (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070908-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-12 | — | — | US | disclosed |
| US-12559494-B2 | Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-0216860-A4 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS. | SUMMERTON JAMES (US) | 1989-02-22 | — | — | EP | disclosed |
| EP-0215942-A4 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. | SUMMERTON JAMES | 1988-08-23 | — | — | EP | disclosed |
| EP-0216860-A1 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS. | SUMMERTON JAMES (US) | 1987-04-08 | — | — | EP | disclosed |
| EP-0215942-A1 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. | SUMMERTON JAMES | 1987-04-01 | — | — | EP | disclosed |
| US-4621145-A | Process for preparing 5-vinyl-2-pyrrolidinone and intermediates therefor | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-11-04 | — | — | US | disclosed |
| WO-1986005519-A1 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD | SUMMERTON JAMES | 1986-09-25 | — | — | WO | disclosed |
| WO-1986005518-A1 | STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS | SUMMERTON JAMES | 1986-09-25 | — | — | WO | disclosed |
| EP-0116257-B1 | PROCESS FOR PREPARING 4-AMINO-5-HEXENOIC ACID | MERRELL DOW FRANCE ET CIE (FR) | 1986-08-27 | — | — | EP | disclosed |
| EP-0116257-A1 | Process for preparing 4-amino-5-hexenoic acid | MERRELL DOW FRANCE ET CIE (FR) | 1984-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092064-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | XDH, MALT1, CBR1 | CRBN 138/4885ALDH1A1 2743/4885SMN1; SMN2 137/4885 |
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | CRBN 39/4885ALDH1A1 4348/4885SMN1; SMN2 1781/4885 |
| US-12559494-B2 | Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR1B, HTR7, HTR6 | CRBN 1418/4885ALDH1A1 3380/4885SMN1; SMN2 3463/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | CRBN 79/4885ALDH1A1 3721/4885SMN1; SMN2 960/4885 |
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR5A | CRBN 2602/4885ALDH1A1 2545/4885SMN1; SMN2 1995/4885 |
| US-20260070908-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, TPH2 | CRBN 2560/4885ALDH1A1 3234/4885SMN1; SMN2 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.